HRA008293
Title:
Integrated Proteogenomic Characterization of Localized Prostate Cancer Identifies Biological Insights and Subtype-Specific Therapeutic Strategies
Release date:
2025-02-24
Description:
We profiled the genome, transcriptome, proteome and phosphoproteome of 145 cases of localized prostate cancer (PCa) in Chinese patients and revealed three subtypes with distinct molecular features: immune subgroup, arachidonic acid metabolic subgroup and sialic acid metabolic subgroup with highest biochemical recurrence (BCR) rates. Further, we revealed that targeting NANS, a key enzyme in sialic acid synthesis, can reverse the immunosuppressive microenvironment through restricting the sialoglycan-sialic acid-recognizing immunoglobulin superfamily lectin (Siglec) axis, thereby inhibiting tumor growth of PCa. We integrated multi-omic data to refine molecular subtyping of localized PCa, and identified NANS as a potential prognostic biomarker and therapeutic option for aggressive PCa.
Data Accessibility:   
Controlled access Request Data
BioProject:
Study type:
Disease Study
Disease name:
prostate cancer
Data Access Committee

For each controlled access study, there is a corresponding Data Access Committee(DAC) to determine the access permissions. Access to actual data files is not managed by NGDC.


DAC NO.:
DAC name:
PCA_WZR3_PRO
Contact person:
Wang Zongren
Email:
wangzr27@mail.sysu.edu.cn
Description:
We profiled the genome, transcriptome, proteome and phosphoproteome of 145 cases of localized prostate cancer (PCa) in Chinese patients and revealed three subtypes with distinct molecular features: immune subgroup, arachidonic acid metabolic subgroup and sialic acid metabolic subgroup with highest biochemical recurrence (BCR) rates. Further, we revealed that targeting NANS, a key enzyme in sialic acid synthesis, can reverse the immunosuppressive microenvironment through restricting the sialoglycan-sialic acid-recognizing immunoglobulin superfamily lectin (Siglec) axis, thereby inhibiting tumor growth of PCa. We integrated multi-omic data to refine molecular subtyping of localized PCa, and identified NANS as a potential prognostic biomarker and therapeutic option for aggressive PCa.
Individuals & samples
Submitter:   Wang Zongren / wangzr27@mail.sysu.edu.cn
Organization:   The First Affiliated Hospital, Sun Yat-sen University
Submission date:   2024-08-13
Requests:   2